Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436380 | 0.92 | DRD4 (0.52) | PROKR1HSD11B1DRD4HSP90AA1HSP90AB1 | |
| SCHEMBL3436624 | 0.91 | DRD4 (0.55) | PROKR1KDM4EHSD11B1DRD4HSP90AA1 | |
| SCHEMBL3435103 | 0.85 | OPRL1 (0.43) | DRD4OPRL1OGFRL1 | |
| SCHEMBL3436370 | 0.85 | DRD4 (0.59) | DRD4OPRL1 | |
| SCHEMBL28853811 | 0.79 | PTPN11 (0.43) | — | |
| SCHEMBL13999718 | 0.78 | KDM4E (0.47) | PROKR1KDM4EHSD11B1DRD4 | |
| SCHEMBL3436379 | 0.77 | HSD11B1 (0.58) | PROKR1HSD11B1DRD4MAPT | |
| SCHEMBL4356330 | 0.76 | CYP3A4 (0.45) | KDM4EDRD4 | |
| SCHEMBL3436055 | 0.76 | DRD4 (0.41) | DRD4OPRL1OGFRL1 | |
| SCHEMBL13416028 | 0.73 | KDM4E (0.49) | PROKR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | PROKR1 987/4885KDM4E 1834/4885HSD11B1 3972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.